Drug development in dementia

Maturitas

Volumn 76, Issue 3, 2013, Pages 260-266

  Cunningham, Emma L ^a   Passmore, Anthony P ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Dementia; Drugs; Therapeutic developments

Indexed keywords

ALZHEIMER DISEASE VACCINE; AVAGACESTAT; BAN 2401; BAPINEUZUMAB; BEGACESTAT; BEXAROTENE; CERE 110; CEREBROLYSIN; CRENEZUMAB; DIMEBON; DONEPEZIL; EXENDIN 4; GANTENERUMAB; GSK 933776; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INSULIN; LADOSTIGIL; LIRAGLUTIDE; LITHIUM; MEMANTINE; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; PONEZUMAB; RO 4909832; SEMAGACESTAT; SOLANEZUMAB; TACRINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BRAIN HEMORRHAGE; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIET SUPPLEMENTATION; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; IMMUNOTHERAPY; LEUKOENCEPHALOPATHY; LIVER TOXICITY; MENINGOENCEPHALITIS; NERVOUS SYSTEM INFLAMMATION; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROTEIN AGGREGATION; PROTEIN PROCESSING; REVIEW;

ALZHEIMER'S DISEASE; ALZHEIMER'S PREVENTION INITIATIVE; API; DEMENTIA; DIAN; DOMINANTLY INHERITED ALZHEIMER'S NETWORK; DRUGS; N-METHYL-D-ASPARTATE; NMDA; RNA BINDING PROTEIN; TDP-43; THERAPEUTIC DEVELOPMENTS;

ALZHEIMER DISEASE; AMYLOID; COGNITION; COGNITION DISORDERS; DEMENTIA; HUMANS; INFLAMMATION; INSULIN; NEUROTRANSMITTER AGENTS; TAU PROTEINS;

EID: 84887428842     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.04.013     Document Type: Review

References (80)

1. G.M. McKhann, D.S. Knopman, and H. Chertkow The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer's & Dementia 7 3 2011 May 263 269
2. M. Prince, and J. Jackson World Alzheimer report Alzheimer's Disease International 2009
3. J.L. Luengo-Fernandez, and Gray A Dementia 2010. The prevalence, economic cost and research funding of dementia compared with other major diseases 2010 Health Economics Research Centre, University of Oxford
4. N.M. Dowling, S. Tomaszewski Farias, and B.R. Reed Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults Journal of the International Neuropsychological Society 17 4 2011 July 602 614
5. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. NICE technology appraisal guidance 217; 2011.
6. A. Alzheimer, R.A. Stelzmann, H.N. Schnitzlein, and F.R. Murtagh An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde" Clinical Anatomy 8 6 1995 429 431
7. D.M. Walsh, and D.J. Selkoe A beta oligomers - a decade of discovery Journal of Neurochemistry 101 5 2007 June 1172 1184
8. Y. Huang, and L. Mucke Alzheimer mechanisms and therapeutic strategies Cell 148 6 2012 March 16 1204 1222
9. M. Morris, S. Maeda, K. Vossel, and L. Mucke The many faces of tau Neuron 70 3 2011 May 12 410 426
10. J.R. Colca, and D.L. Feinstein Altering mitochondrial dysfunction as an approach to treating Alzheimer's disease Advances in Pharmacology 64 2012 155 176
11. G.G. Glenner, and C.W. Wong Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein Biochemical & Biophysical Research Communications 122 3 1984 August 16 1131 1135
12. R.E. Tanzi, and L. Bertram Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective Cell 120 4 2005 February 25 545 555
13. L.A. Farrer, L.A. Cupples, and J.L. Haines Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium JAMA 278 16 1997 October 22-29 1349 1356
14. R.W. Mahley, and Y. Huang A polipoprotein e sets the stage: response to injury triggers neuropathology Neuron 76 5 2012 December 6 871 885
15. S. Seshadri, A.L. Fitzpatrick, and M.A. Ikram Genome-wide analysis of genetic loci associated with Alzheimer disease JAMA 303 18 2010 May 12 1832 1840
16. L. Jones, P.A. Holmans, and M.L. Hamshere Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease PLoS ONE 5 11 2010 e13950 [Electronic resource]
17. B. Dubois, H.H. Feldman, and C. Jacova Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurology 9 11 2010 November 1118 1127
18. R.A. Sperling, P.S. Aisen, and L.A. Beckett Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer's & Dementia 7 3 2011 May 280 292
19. C.R. Jack Jr., D.S. Knopman, and W.J. Jagust Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurology 12 2 2013 February 207 216
20. S.A. Ligthart, E.P. Moll van Charante, W.A. van Gool, and E. Richard Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review Vascular Health & Risk Management 6 2010 775 785
21. M.L. Daviglus, C.C. Bell, and W. Berrettini National institutes of health state-of-the-science conference statement: preventing Alzheimer disease and cognitive decline Annals of Internal Medicine 153 3 2010 August 3 176 181
22. N.T. Lautenschlager, K.L. Cox, and L. Flicker Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial JAMA 300 9 2008 September 3 1027 1037
23. B. McGuinness, D. Craig, R. Bullock, and Passmore P Statins for the prevention of dementia Cochrane Database of Systematic Reviews 2 2009 003160
24. B. McGuinness, J. O'Hare, D. Craig, R. Bullock, R. Malouf, and Passmore P Statins for the treatment of dementia Cochrane Database of Systematic Reviews 8 2010 007514
25. D. Jaturapatporn, M. Isaac, J. McCleery, and N. Tabet Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease Cochrane Database of Systematic Reviews 2 2012 006378
26. E. Hogervorst, K. Yaffe, M. Richards, and F.A. Huppert Hormone replacement therapy to maintain cognitive function in women with dementia Cochrane Database of Systematic Reviews 1 2009 03799
27. S. Weggen, J.L. Eriksen, and P. Das A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414 6860 2001 November 8 212 216
28. R.C. Green, L.S. Schneider, and D.A. Amato Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 23 2009 December 16 2557 2564
29. T.E. Golde, L.S. Schneider, and E.H. Koo Anti-a therapeutics in Alzheimer's disease: the need for a paradigm shift Neuron 69 2 2011 January 27 203 213
30. Press release regarding study termination 2010. http://newsroom.lilly. com/releasedetail.cfm?releaseid=499794.
31. Press release regarding follow up data presented to the Alzheimer's association international conference 2011. http://newsroom.lilly.com/ releasedetail.cfm?releaseid=592438.
32. Statement on company website 2012. http://www.bms.com/news/features/2012/ Pages/AvagacestatDevelopmentStatus.aspx.
33. V. Coric, C.H. van Dyck, and S. Salloway Safety and tolerability of the γ-secretase inhibitor avagacestat in a Phase 2 study of mild to moderate Alzheimer disease Archives of Neurology 69 11 2012 November 1430 1440
34. C. Harrington, S. Sawchak, and C. Chiang Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two Phase 3 studies Current Alzheimer Research 8 5 2011 August 592 606
35. B. Vellas, O. Sol, and P.J. Snyder EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study Current Alzheimer Research 8 2 2011 203 212
36. J.M. Orgogozo, S. Gilman, and J.F. Dartigues Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 1 2003 July 8 46 54
37. C. Holmes, D. Boche, and D. Wilkinson Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase 1 trial Lancet 372 9634 2008 July 19 216 223
38. Johnson&Johnson press release 2012 regarding halting of bapineuzumab trials. http://www.jnj.com/connect/news/all/johnson-and-johnson-announces- discontinuation-of-phase-3-development-of-bapineuzumab-intravenous-iv-in-mild- to-moderate-alzheimers-disease.
39. S. Salloway, R. Sperling, and S. Gilman A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 24 2009 December 15 2061 2070
40. R. Sperling, S. Salloway, and M. Arrighi Revised estimates of incidence and risk factors for amyloid related imaging abnormalities (ARIA) in the Phase 2 studies of bapineuzumab for mild-to-moderate Alzheimer's disease Alzheimer's & Dementia: The Journal of the Alzheimer's Association 7 4, Suppl. 2011 e64
41. Eli Lilly press release 2012 regarding solanezumab Phase 3 results. https://investor.lilly.com/releaseDetail.cfm?ReleaseID=702211.
42. Tom Fagan and Gabrielle Strobel reporting the American Neurological Association, 2012, where Rachel Doody spoke for the ADCS regarding solanazumab and Reisa Sperling spoke regarding bapineuzumab. http://www.alzforum.org/new/ detail.asp?id=3288.
43. News item regarding selection of drugs for DIAN study 2012. http://www.alzforum.org/new/detail.asp?id=3289.
44. K. Garber Genentech's Alzheimer's antibody trial to study disease prevention Nature Biotechnology 30 8 2012 731 732
45. B. Bohrmann, K. Baumann, and J. Benz Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β Journal of Alzheimers Diseases 28 1 2012 49 69
46. Question & Answer session with Ryan Watts, Genentech and Gabrielle Strobel, alzforum 2012. http://www.alzforum.org/new/detail.asp?id=3156.
47. S.L. La Porte, S.S. Bollini, and T.A. Lanz Structural basis of C-terminal-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease Journal of Molecular Biology 421 4/5 2012 August 24 525 536
48. R. Dodel, A. Rominger, and P. Bartenstein Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a Phase 2, randomised, double-blind, placebo-controlled dose-finding trial Lancet Neurology S1474-S4422 13 2013 70014
49. P.S. Aisen, S. Gauthier, and S.H. Ferris Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Archives of Medical Science 7 1 2011 February 102 111
50. E.L. Sampson, L. Jenagaratnam, and R. McShane Metal protein attenuating compounds for the treatment of Alzheimer's dementia Cochrane Database of Systematic Reviews 5 2012 005380
51. P.N. Tariot, L.S. Schneider, and J. Cummings Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Archives of General Psychiatry 68 8 2011 August 853 861
52. H. Hampel, M. Ewers, and K. Burger Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study Journal of Clinical Psychiatry 70 6 2009 June 922 931
53. T. Gura Hope in Alzheimer's fight emerges from unexpected places Nature Medicine 14 9 2008 September 894
54. R.H. Schirmer, H. Adler, M. Pickhardt, and Mandelkow E Lest we forget you - methylene blue Neurobiology Aging 32 12 2011 December 2325.e7 2325.e16
55. McClean PL. Liraglutide is neuroprotective in chronic treatment in an APP/PS1 mouse model of Alzheimer's disease. Alzheimer's Research UK Conference 2013.
56. A. Corbett, J. Pickett, and A. Burns Drug repositioning for Alzheimer's disease Nature Reviews. Drug Discovery 11 11 2012 833 846
57. S. Craft, J. Newcomer, and S. Kanne Memory improvement following induced hyperinsulinemia in Alzheimer's disease Neurobiology of Aging 17 1 1996 January-February 123 130
58. E. Tobinick, H. Gross, A. Weinberger, and H. Cohen TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study Medgenmed [Computer File]: Medscape General Medicine 8 2 2006 25
59. E. Tobinick Perispinal etanercept for neuroinflammatory disorders Drug Discovery Today 14 3/4 2009 February 168 177
60. P.T. Nguyen, T. Kimura, S.A. Ho, A.H. Tran, T. Ono, and H. Nishijo Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-beta peptide (1-40) in rats Hippocampus 17 6 2007 443 455
61. R.J. Mandel CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease Current Opinion in Molecular Therapeutics 12 2 2010 April 240 247
62. X.A. Alvarez, R. Cacabelos, and C. Sampedro Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin European Journal of Neurology 18 1 2011 January 59 68
63. P.E. Cramer, J.R. Cirrito, and D.W. Wesson ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 335 6075 2012 March 23 1503 1506
64. A.W. Laxton, D.F. Tang-Wai, and M.P. McAndrews A Phase 1 trial of deep brain stimulation of memory circuits in Alzheimer's disease Annals of Neurology 68 4 2010 October 521 534
65. R. Howard, R. McShane, and J. Lindesay Donepezil and memantine for moderate-to-severe Alzheimer's disease New England Journal of Medicine 366 10 2012 March 8 893 903
66. A. Romero, R. Cacabelos, M.J. Oset-Gasque, A. Samadi, and J. Marco-Contelles Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease BMCL Letters 23 2013 1916 1922
67. O. Weinreb, T. Amit, O. Bar-Am, and M.B. Youdim Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment Current Drug Targets 13 4 2012 April 483 494
68. http://www.clinicaltrials.gov/ct2/show/results/NCT00744978?term= varenicline+alzheimer&rank=1§=X43015#othr.
69. Company press release regarding CONNECTION study 2010. http://investors.medivation.com/releasedetail.Cfm?ReleaseID=448818.
70. News item regarding results of CONCERT study 2012. http://www.alzforum. org/new/detail.asp?id=3032.
71. A. Salva, S. Andrieu, and E. Fernandez Health and nutritional promotion program for patients with dementia (NutriAlz Study): design and baseline data The Journal of Nutrition, Health & Aging 13 6 2009 June 529 537
72. C.A. de Jager, A. Oulhaj, R. Jacoby, H. Refsum, and A.D. Smith Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial International Journal of Geriatric Psychiatry 27 6 2012 June 592 600
73. N. Farina, M.G. Isaac, A.R. Clark, J. Rusted, and N. Tabet Vitamin E for Alzheimer's dementia and mild cognitive impairment Cochrane Database of Systematic Reviews 11 2012 002854
74. D.R. Galasko, E. Peskind, and C.M. Clark Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures Archives of Neurology 69 7 2012 July 836 841
75. B. Vellas, N. Coley, and P.J. Ousset Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial Lancet Neurology 11 10 2012 October 851 859
76. P. Scheltens, P.J. Kamphuis, and F.R. Verhey Efficacy of a medical food in mild Alzheimer's disease: a randomized controlled trial Alzheimers Dementia 6 1 2010 1 10.e1
77. P.J. Kamphuis, F.R. Verhey, M.G. Olde Rikkert, J.W. Twisk, S.H. Swinkels, and P. Scheltens Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial The Journal of Nutrition, Health & Aging 15 8 2011 720 724
78. P. Scheltens, J.W. Twisk, and R. Blesa Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial Journal of Alzheimer's Disease 31 1 2012 225 236
79. N. Kozauer Guidance for industry Alzheimer's disease: developing drugs for the treatment of early stage disease. Draft guidance 2013 US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Maryland, USA
80. U. Muller, P. Winter, and M.B. Graeber A presenilin 1 mutation in the first case of Alzheimer's disease Lancet Neurology 12 2 2013 February 129 130